Analysts expect Intec Pharma Ltd (NASDAQ:NTEC) to post earnings per share of ($0.37) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Intec Pharma’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.38). Intec Pharma reported earnings of ($0.41) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 9.8%. The firm is scheduled to issue its next earnings report on Tuesday, May 21st.

According to Zacks, analysts expect that Intec Pharma will report full year earnings of ($1.15) per share for the current year, with EPS estimates ranging from ($1.25) to ($1.01). For the next year, analysts anticipate that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.19) to ($0.68). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Intec Pharma.

Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08).

NTEC has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Intec Pharma in a research report on Friday, January 4th. BidaskClub lowered Intec Pharma from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 16th. LADENBURG THALM/SH SH restated a “buy” rating and issued a $15.00 price target on shares of Intec Pharma in a research report on Thursday, February 28th. ValuEngine upgraded Intec Pharma from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Oppenheimer set a $15.00 price target on Intec Pharma and gave the stock a “buy” rating in a research report on Friday, February 22nd. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $12.46.

Shares of NASDAQ:NTEC traded up $0.13 during midday trading on Friday, hitting $6.39. The company had a trading volume of 123,861 shares, compared to its average volume of 206,769. Intec Pharma has a 12 month low of $3.55 and a 12 month high of $9.25. The firm has a market capitalization of $209.76 million, a P/E ratio of -4.56 and a beta of 0.40.

A number of hedge funds have recently bought and sold shares of NTEC. PRW Wealth Management LLC purchased a new position in Intec Pharma in the 4th quarter worth about $29,000. BlackRock Inc. purchased a new position in Intec Pharma during the 4th quarter valued at about $67,000. Essex Investment Management Co. LLC purchased a new position in Intec Pharma during the 4th quarter valued at about $2,972,000. Reilly Financial Advisors LLC purchased a new position in Intec Pharma during the 4th quarter valued at about $38,000. Finally, PNC Financial Services Group Inc. increased its position in Intec Pharma by 50.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 75,000 shares of the biotechnology company’s stock valued at $424,000 after purchasing an additional 25,000 shares during the period. Hedge funds and other institutional investors own 36.43% of the company’s stock.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: Bear Market

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.